Clinical-stage biotechnology company BriaCell Therapeutics (TSX.V: BCT) (OTCQB: BCTXF) has achieved proof of concept and recently reported promising results from its Phase IIa study of its lead clinical candidate, Bria-IMT. An article further discussing the company reads, “A total of 31 patients with advanced stage breast cancer were enrolled in the Phase II Bria-IMT monotherapy study. The proof of concept and mechanism of action work is based on the results observed in the first 20 patients, while assessment of the remaining 11 patients is still in progress. …The preliminary data seems to confirm the company’s HLA Matching Hypothesis and support its strategy for the development of Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer, designed to provide treatment without the high costs and difficult manufacturing generally associated with personalized therapies. The technology is applicable to other types of cancer, as well.” A combination study with immune checkpoint inhibitors is in the works and enrollment is already open.
To view the full article, visit http://nnw.fm/OfeQ9
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
